Proactive Investors - Run By Investors For Investors

Pharmaxis reveals first sales of Aridol® in US following successful relaunch

Aridol is a lung function test designed to help doctors diagnose and manage asthma.
body imagine showing the human lungs
Shares last traded up 3.8% intra-day to 27 cents

Pharmaxis Ltd (ASX:PXS) has achieved the first sales of its asthma diagnostic test Aridol® in the US following the relaunch of the product.

This follows US FDA approval in August 2018 for its Sydney manufacturing facility to produce and supply Aridol to the US through its exclusive distribution partner Methapharm Inc.

Methapharm has extensive experience in the sales channels and specialist centres that conduct lung function testing.

READ: Pharmaxis receives FDA approval to produce Aridol for US market

Pharmaxis’s CEO Gary Phillips said, “Aridol was approved by the FDA in 2011 to identify bronchial hyperresponsiveness and commercialised by Pharmaxis in the US until its withdrawal from the market in 2013 as part of a corporate restructuring when we closed the facility used to manufacture Aridol for the US.

“Two years ago Pharmaxis partnered with Methapharm to re‐enter the US market and commenced the validation work required to have our remaining manufacturing facility approved by the FDA for Aridol. 

“Both Methapharm and Pharmaxis believe there remains a strong need in the US for objective tests to aid physicians in diagnosing asthma. It’s good to be back.”

Advancing partnership talks for LOXL2

Pharmaxis has a portfolio of drugs ranging from the pre-clinical phase through to the clinical phase and finally drugs in the commercial phase such as Aridol® and Bronchitol®.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use